NewsNuggs.com Fire Emoji Icon
  Stay informed, not overwhelmed!

HIVPrevention Trending News

Everything you want to know about HIVPrevention in 42-word summarized news nuggets

HIV Breakthrough Drug Faces Rollout Hurdles in Uganda

#HIVPrevention #GlobalHealth

Lenacapavir, a twice-yearly HIV prevention injection, shows unprecedented efficacy in Uganda trials. However, rollout faces criticism over limited access, high costs, and funding cuts, leaving many communities vulnerable despite the drug's promise. read more


Older HIVPrevention News Nuggs

Cambodia First in Asia to Hit HIV Treatment Target

#HIVPrevention #GlobalHealth

Cambodia became the first Asian nation to reach UNAIDS' 95-95-95 HIV targets, with 95% knowing status, on treatment, and virally suppressed. Success came from political will, community-led outreach, and stigma reduction, despite challenges across wealthier Asian countries. read more

Africa to Produce New HIV Prevention Drugs Locally

#GlobalHealth #HIVPrevention

Kenya, Uganda, and South Africa will receive Unitaid support to manufacture next-generation HIV prevention drugs like alimatravir, reducing reliance on imports. This aims to build resilient supply chains amid US aid cuts that closed clinics and disrupted access. read more

South Africa Launches HIV Prevention Shot Amid Funding Crisis

#HIVPrevention #GlobalHealth

South Africa launched Lenacapavir, a biannual HIV prevention injection, hailed as a game-changer. However, U.S. aid cuts and high costs limit access. Generic versions expected by 2027 at $40 yearly could drastically cut infections if widely adopted. read more

Lenacapavir: Twice-Yearly Shot Could Transform HIV Fight

#HIVPrevention #GlobalHealth

A long-acting HIV prevention injection offers hope for adolescent girls and young women in sub-Saharan Africa, removing daily pill burdens. Scaling up access through local production and affordable pricing could transform epidemic control and empower a generation. read more

Twice-Yearly HIV Shot Offers New Hope to Africa

#Lenacapavir #HIVPrevention

A groundbreaking twice-yearly HIV prevention injection, lenacapavir, is rolling out in Eswatini. It offers near-complete protection, raising hopes to end the AIDS pandemic despite US aid cuts threatening broader access and global effectiveness. read more

HIV Funding Cuts Risk 10% Surge in U.S. Infections

#HIVPrevention #PublicHealthFunding

Proposed CDC funding cuts could increase U.S. HIV infections by 10% over five years, researchers warn. Over 1.2 million Americans live with HIV. Cuts threaten prevention programs, risking more transmissions and deaths. read more

HIV Prevention Shot Fails Kenyas Poorest

#HealthEquity #HIVPrevention

Kenya's rollout of the groundbreaking HIV prevention drug lenacapavir is failing to reach high-risk areas like Kibera. Despite its potential, high transport costs and clinic exclusions leave the most vulnerable without access, highlighting an equity gap in healthcare delivery. read more

UK Aid Cuts Imperil HIV Prevention Breakthrough

#HIVPrevention #GlobalHealthJustice

UK aid cuts threaten the rollout of Lenacapavir, a groundbreaking HIV prevention drug. This jeopardizes progress in sub-Saharan Africa, where women and girls face disproportionate risk. Political choices now determine if this medical breakthrough reaches those who need it most. read more

New HIV Shot Offers Hope Amid Funding Crisis

#HIVPrevention #GlobalHealth

A groundbreaking twice-yearly HIV prevention injection, lenacapavir, is rolling out in Eswatini and eight other high-risk nations. Hailed as a potential pandemic-ender, its limited global scale and funding cuts threaten its lifesaving impact. read more

Trump Administration Considers Deep Cuts to HIV Prevention Program

#HIVprevention #Trumpadministration

The Trump administration considers significant cuts to the CDC's HIV prevention program, sparking concerns from advocacy groups. Funding reductions could reverse progress in combating the HIV epidemic, jeopardizing lives and hindering the administration's goal to end the epidemic by 2030. read more